Back to Search
Start Over
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
- Source :
-
Leukemia & Lymphoma . Jun2020, Vol. 61 Issue 6, p1323-1333. 11p. - Publication Year :
- 2020
-
Abstract
- The Intergroupe Francophone du Myelome 2009 trial (NCT01191060) assessed health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) receiving lenalidomide/bortezomib/dexamethasone (RVd) induction therapy followed by consolidation therapy with either autologous stem cell transplantation (ASCT) plus RVd (RVd-ASCT) or RVd-alone; both groups then received lenalidomide maintenance therapy for 1 year. Global HRQoL, physical functioning, and role functioning scores significantly improved for both cohorts from baseline to the end of consolidation and were sustained during maintenance and follow-up, with clinically meaningful changes (RVd-alone: p =.0002; RVd-ASCT: p <.001). Similarly, both groups showed clinically meaningful improvements from baseline in fatigue, pain, and disease symptom scores. Side effects of treatment scores remained stable. In the RVd-ASCT group, there was transient worsening in HRQoL immediately after ASCT. These findings suggest that the clinical improvements observed with RVd-based treatment are accompanied by overall improvements in HRQoL for patients with NDMM. [ABSTRACT FROM AUTHOR]
- Subjects :
- *QUALITY of life
*MULTIPLE myeloma
*STEM cell transplantation
*BORTEZOMIB
*SYMPTOMS
Subjects
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 61
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 144283138
- Full Text :
- https://doi.org/10.1080/10428194.2020.1719091